Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Afrezza 8 Un Powder 90 By Mannkind

NDC No. 47918-0878-90 47918-878-90 UPC/GTIN No. 3-47918-88018-9 MPN No. 088018 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist,Aventis PharmaceuticalsOnly Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Image 5 of Rx Item-Afrezza 8 Un Powder 90 By Mannkind

Rx Item-Afrezza 8 Un Powder 90 By Mannkind

$1021.09$879.99

Item No.:RX678433, Item No. RX678433, 678433, NDC No.: 47918-0878-90, 47918-878-90, 4791887890, 47918087890, 0878-90, 087890 UPC No. 3-47918-87890-2, 347918-878902, 347918878902, Rx Item-Afrezza 8 Un Powder 90 By Mannkind Only Physician, Pharmacy Or Licensed Facility Can purchase this RX Item Brand/Generic: Brand, Drug Category: Metabolic Agents -Antidiabetic Agents-Insulin Drug Class: 68200804 Rapid- Acting Insulins
68200800 Insulin

Have a question?

Clinical Information
Gen. Code and Des.
73243 insulin regular, human INHALATION CART INHAL 8 UNIT
GCN and Des.
37621 insulin regular, human INHALATION CART INHAL 8 UNIT
Strength
8UN
Dose Form
CARTRIDGE WITH INHALER
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family

AHFS Class
68200804 RAPID-ACTING INSULINS
68200800 INSULINS
Active Ingredients
869 insulin regular, human 11061680
Inactive Ingredients
2551 polysorbates 9005645





Item info. These highlights do not include all the info. needed to use AFREZZA safely and effectively. See full prescribing info. for AFREZZA . AFREZZA (insulin human) Inhalation Powder Initial U.S. Approval: 2014 WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE See full prescribing info. for complete boxed warning. Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating AFREZZA, perform detailed medical history, physical examination, and spirometry (FEV ) to identify potential lung disease in all patients. , INDICATIONS AND USAGE AFREZZA is rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Important limitations of use: In patients with type diabetes, must use with long-acting insulin. Not recommended for the treatment of diabetic ketoacidosis. Not recommended in patients who smoke DOSAGE AND ADMINISTRATION Administer using single inhalation per cartridge Administer at the beginning of meal Dosing must be individualized Before initiating, perform detailed medical history, physical examination, and spirometry (FEV ) in all patients to identify potential lung disease DOSAGE FORMS AND STRENGTHS AFREZZA is available as single-use cartridges of: 4 units 8 units 12 units CONTRAINDICATIONS During episodes of hypoglycemia Chronic lung disease, such as asthma, or chronic obstructive pulmonary disease Hypersensitivity to regular human insulin or any of the AFREZZA excipients ARNINGS AND PRECAUTIONS Acute Bronchospasm: Acute bronchospasm has been observed in patients with asthma and COPD. Before initiating, perform spirometry (FEV ) in all patients. Do not use in patients with chronic lung disease. (2.5, 4, 5.1) Change in Insulin Regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring. Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairment and hypoglycemia unawareness. (5.3, 6, 7, 8.6, 8.7) Decline in Pulmonary Function: Assess pulmonary function (e.g., spirometry) before initiating, after months of therapy, and annually, even in the absence of pulmonary symptoms. (2.5, 5.4) Lung Cancer: AFREZZA should not be used in patients with active lung cancer. In patients with history of lung cancer or at risk for lung cancer, the benefit of AFREZZA use should outweigh this potential risk. Diabetic Ketoacidosis: More patients using AFREZZA experienced diabetic ketoacidosis in clinical trials. In patients at risk for DKA, monitor and change to alternate route of insulin delivery, if indicated. Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA. Discontinue AFREZZA, monitor and treat if indicated. Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated. Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. ADVERSE REACTIONS The most common adverse reactions associated with AFREZZA (2% or greater incidence) are hypoglycemia, cough, and throat pain or irritation. To report SUSPECTED ADVERSE REACTIONS, contact MannKind at (1-877-323-8505) or FDA at (1-800-FDA-1088) or www.fda.gov/medwatch. DRUG INTERACTIONS Drugs that Affect Glucose Metabolism: Adjustment of insulin dosage may be needed. (7.1, 7.2, 7.3) Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of hypoglycemia may be reduced or absent. (7.3, 7.4) See 17 for PATIENT COUNSELING info. and Medication Guide. Revised: 04/201

NDC No. 47918-0878-90 47918-878-90 UPC/GTIN No. 3-47918-88018-9 MPN No. 088018 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist,
Rx Item-Afrezza 8 Un Powder 90 By Mannki
NDC No. 47918-0878-90 47918-878-90 UPC/GTIN No. 3-47918-88018-9 MPN No. 088018 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist,

Aventis Pharmaceuticals
AmericanPharmaWholesale.com
Aventis Pharmaceuticals

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
INSULIN REGULAR, HUMAN IN
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.